سعر نوفوميكس 30 100 وحدة /مل 5 اقلام معبأة 2025

NovoMix 30 100 units/ml, 5 pre-filled pens (FlexPen), 3 ml each (300 units per pen) (Novo Nordisk): biphasic suspension of 30% soluble insulin aspart and 70% protamine-crystallised insulin aspart for subcutaneous injection.

• Treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.Population: Adults, adolescents and children aged 10 years and aboveEuropean Medicines Agency (EMA)
• To improve glycemic control in adult patients with diabetes mellitus; not recommended for diabetic ketoacidosis; fixed proportions do not allow separate basal/prandial adjustment.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Hypoglycaemia is very common. Uncommon: urticaria, rash, eruptions; refraction disorders; diabetic retinopathy; lipodystrophy; oedema; injection site reactions. Rare: peripheral (painful) neuropathy. Very rare: anaphylactic reactions. Not known: cutaneous amyloidosis.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to the active substance or to any of the excipients.International label, same product · European Medicines Agency (EMA)
• During episodes of hypoglycemia; hypersensitivity to NOVOLOG MIX 70/30 or one of its excipients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypoglycaemia (omitted meal, unplanned strenuous exercise, dose too high); do not inject during hypoglycaemia. May have a more pronounced glucose-lowering effect up to 6 hours after injection than biphasic human insulin. Warning symptoms may change after improved control or transfer between insulins.International label, same product · European Medicines Agency (EMA)
• Hyperglycaemia and diabetic ketoacidosis may follow inadequate dosing or discontinuation, especially in type 1 diabetes.International label, same product · European Medicines Agency (EMA)
• Transfer to another insulin type or brand must be under strict medical supervision and may require dose changes.International label, same product · European Medicines Agency (EMA)

• Oral antidiabetics, GLP-1 receptor agonists, MAOIs, beta-blockers, ACE inhibitors, salicylates, anabolic steroids, sulfonamidesMay reduce insulin requirements.European Medicines Agency (EMA)
• Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone, danazolMay increase insulin requirements.European Medicines Agency (EMA)
• Beta-blockersMay mask the symptoms of hypoglycaemia.European Medicines Agency (EMA)

• Limited clinical experience in pregnancy; animal studies showed no difference between insulin aspart and human insulin in embryotoxicity or teratogenicity. Intensified glucose control and monitoring are recommended throughout pregnancy and when planning pregnancy.International label, same product · European Medicines Agency (EMA)
• No available data with NOVOLOG MIX 70/30 in pregnant women; published trials of insulin aspart in the second trimester have not reported an association with major birth defects or adverse maternal or fetal outcomes; poorly controlled diabetes carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No restrictions during breast-feeding; insulin treatment of the nursing mother presents no risk to the baby, but the dose may need adjustment.International label, same product · European Medicines Agency (EMA)

• Insulin aspart (soluble): Lowers blood glucose by facilitating glucose uptake after binding to insulin receptors on muscle and fat cells and by inhibiting hepatic glucose output (EU NovoMix 30 SmPC 5.1).
• Insulin aspart protamine (protamine-crystallised insulin aspart): Lowers blood glucose by facilitating glucose uptake after binding to insulin receptors on muscle and fat cells and by inhibiting hepatic glucose output (EU NovoMix 30 SmPC 5.1).